Core Viewpoint - Rakovina Therapeutics Inc. reported its financial results for Q2 2025, highlighting advancements in AI-powered drug discovery for cancer therapies and recent corporate developments [1]. Financial Highlights - Cash and cash equivalents as of June 30, 2025, were CAD 1.88 million, an increase from CAD 1.31 million as of December 31, 2024 [5]. - Working capital improved to CAD 622,851 from CAD 321,442 [5]. - Total assets increased to CAD 6.55 million from CAD 6.24 million [5]. - Total liabilities rose significantly to CAD 3.34 million from CAD 1.94 million [5]. - The net loss for Q2 2025 was CAD 2.92 million, compared to a loss of CAD 820,720 in Q2 2024 [8]. Research and Development Expenses - R&D expenses for Q2 2025 were CAD 1.61 million, a substantial increase from CAD 479,785 in Q2 2024 [8]. - General and administrative expenses were CAD 1.21 million, up from CAD 276,183 [8]. Corporate Developments - The company closed a non-brokered private placement on June 6, 2025, raising approximately CAD 3.56 million [7]. - A reverse share consolidation was implemented on June 24, 2025, at a ratio of 1-for-10, resulting in 21,148,039 common shares outstanding as of June 30, 2025 [7]. - On June 30, 2025, the company announced intentions to amend certain outstanding warrants and convertible debentures totaling CAD 1.45 million, pending TSXV approval [7]. - A warrant exercise incentive program was announced on July 24, 2025, to encourage early exercise of certain outstanding warrants [7]. Stock Options - The company granted 540,000 stock options post-consolidation to various stakeholders, exercisable at CAD 0.70 per share with a vesting period of six months over three years [7].

WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in September 2025: The Cantor Global Healthcare Conference 2025 in New York City on Wednesday, September 3, 2025. A corporate presentation is scheduled for 3:55 p.m. Eastern Time. The 2025 Wells Fargo Healthcare Conference in Boston on Thursday, September 4, 2025. A corporate presentation is scheduled for 4:30 p.m. Easter ...

NEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that its management is scheduled to participate in upcoming September investor conferences. Details of the Company’s participation are as follows: Cantor Global Healthcare Conference 2025 Format: Fireside ChatDate: Friday, September 5th at 8 ...

COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available ...

PureTech Health (PRTC) H1 2025 Earnings Call August 28, 2025 09:00 AM ET Company ParticipantsAllison Talbot - SVP - CommunicationsRobert Lyne - Interim CEOSven Dethlefs - CEO - Celea TherapeuticsLuba Greenwood - CEOHeidi Jacobson - Equity Research AssociateEric Elenko - Co-Founder & PresidentConference Call ParticipantsMiles Dixon - Research Analyst - Healthcare & Life SciencesOperatorHello, everyone, and thank you for joining the Puretec Health twenty twenty five Half Year Earnings Webcast. My name is Samm ...

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been ...

Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlights the depth of its oncology and immunotherapy pipeline while recognizing the extraordinary intellectual property contributions of its Chairman and CEO, Dr. Vuo ...

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date/ time: Tuesday, September 9 at 3:30 PM  ...

Dr. Steven Quay, Chairman and Chief Executive Officer to participate in Fireside Chat with Emily Bodnar, HCW Biotech Research AnalystSEATTLE, Aug. 28, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announced that Dr. Steven Quay, Chairman and Chief Executive Officer, will participate in a fireside chat with biotech research analyst, Emily Bodnar, a ...

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September. Cantor Global Healthcare Conference Date:September 5, 2025Time:8:35am EasternFormat:Fireside ChatWebcast:Link to webc ...